Enhancer of zeste 2 polycomb repressive complex 2 subunit
Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is a catalytic component of the Polycomb repressive complex 2 (PRC2), an epigenetic regulatory complex that promotes transcriptional repression through trimethylation of histone H3 at lysine 27 (H3K27me3).
Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is a catalytic component of the Polycomb repressive complex 2 (PRC2), an epigenetic regulatory complex that promotes transcriptional repression through trimethylation of histone H3 at lysine 27 (H3K27me3). By influencing chromatin state and gene expression, EZH2 participates in the regulation of cellular identity, proliferation, and phenotypic plasticity. Its activity is also studied in relation to DNA methylation, m6A-modified RNA, long noncoding RNAs, and extracellular-vesicle-mediated signaling.
EZH2 is investigated as a disease-associated molecule and therapeutic target in cancers including triple-negative breast cancer, prostate cancer, lymphoma, and colorectal cancer, as well as in sepsis-associated lung injury and gestational diabetes. Recent preclinical work has examined EZH2-directed strategies alone or in combination with epidermal growth factor receptor (EGFR), histone deacetylase (HDAC), and mechanistic target of rapamycin complex 1 (mTORC1) pathway interventions. Other studies have evaluated EZH2 regulation by miR-124, the lncRNA MEG8/WNT7A axis, lactylation, and extracellular vesicles, reflecting the diverse biological contexts in which EZH2-dependent gene regulation is being explored.
Where the papers sit
9 papers from the last 6 months study enhancer of zeste 2 polycomb repressive complex 2 subunit directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 human data · 7 preclinical · 1 unclassified
Themes no clear themes
Those 9 do not share a common subject.
-
EZH2 is the sole common thread across studies of cancer, sepsis-associated lung injury, gestational diabetes and inflammatory disease. Individual papers address lactylation, DNA methylation, extracellular-vesicle miR-124 delivery, mTORC1 vulnerability and EZH2/HDAC or EZH2/EGFR inhibition. The diseases, mechanisms and therapeutic strategies differ substantially, with no shared clinical endpoint or consistent direction of travel. Together, the group reflects broad exploratory interest in EZH2 rather than one coherent research question.
Papers
The 9 papers from the last 6 months that study enhancer of zeste 2 polycomb repressive complex 2 subunit directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- Synthesis, in silico, in vitro and in vivo evaluation of novel thiophene[3,2-b]indole-based potential EZH2 modulators as anti-inflammatory agents. Bioorganic chemistry · 29 Oct 2026 PMID 42956582
- EZH2 lactylation: a key epigenetic regulator and potential therapeutic target for sepsis-associated lung injury. Journal of advanced research · 27 Oct 2026 PMID 42946159
- Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
- Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling. Medical oncology (Northwood, London, England) · 8 Oct 2026 PMID 42848258
- EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. Cell reports. Medicine · 30 Sept 2026 PMID 42815467
- METTL14 alleviates pyroptosis of placental trophoblasts in gestational diabetes mellitus through the lncRNA MEG8/WNT7A axis via m6A modification. Functional & integrative genomics · 11 Sept 2026 PMID 42726311
- Bovine Colostrum-Derived Extracellular Vesicles Impair Cancer Cell Proliferation Through Transcriptional Dysregulation. Journal of extracellular vesicles · 1 Sept 2026 PMID 42680698
- Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
- Design, synthesis and biological evaluation of EZH2/HDAC dual inhibitors for the treatment of lymphomas. European journal of medicinal chemistry · 13 Jun 2026 PMID 42288027
By study type
Human data, design not indexed (1)
- Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
Preclinical: animal, cell and lab studies (7)
- Synthesis, in silico, in vitro and in vivo evaluation of novel thiophene[3,2-b]indole-based potential EZH2 modulators as anti-inflammatory agents. Bioorganic chemistry · 29 Oct 2026 PMID 42956582
- Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling. Medical oncology (Northwood, London, England) · 8 Oct 2026 PMID 42848258
- EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. Cell reports. Medicine · 30 Sept 2026 PMID 42815467
- METTL14 alleviates pyroptosis of placental trophoblasts in gestational diabetes mellitus through the lncRNA MEG8/WNT7A axis via m6A modification. Functional & integrative genomics · 11 Sept 2026 PMID 42726311
- Bovine Colostrum-Derived Extracellular Vesicles Impair Cancer Cell Proliferation Through Transcriptional Dysregulation. Journal of extracellular vesicles · 1 Sept 2026 PMID 42680698
- Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
- Design, synthesis and biological evaluation of EZH2/HDAC dual inhibitors for the treatment of lymphomas. European journal of medicinal chemistry · 13 Jun 2026 PMID 42288027
Unclassified: not yet indexed with MeSH (1)
- EZH2 lactylation: a key epigenetic regulator and potential therapeutic target for sepsis-associated lung injury. Journal of advanced research · 27 Oct 2026 PMID 42946159
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-11-09. Drafted by language models from published abstracts; not medical advice.